ArticleMolecular cancer therapeutics2022

Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.

Didier Scherrer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.